Triple-Drug cocktail targets rare kidney cancers
NCT ID NCT04413123
First seen Jan 21, 2026 · Last updated May 13, 2026 · Updated 17 times
Summary
This study tests whether a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) can safely slow the growth of advanced or spreading kidney cancer in people with rare types of the disease. About 60 adults with non-clear cell kidney cancer that cannot be surgically removed or has spread will receive the treatment. The goal is to see how many patients' tumors shrink or disappear, and how long that effect lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Brigham & Woman's Hospital
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
UT Southwestern Medical
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.